Lunesta FDA Approval History

When Was Lunesta Approved by the FDA?

The FDA approved eszopiclone (brand name Lunesta) on December 15, 2004. Sunovion Pharmaceuticals (then operating as Sepracor Inc.) received approval under New Drug Application (NDA) 021476. The approval covered three tablet strengths: 1 mg, 2 mg, and 3 mg, all indicated for the treatment of insomnia characterized by difficulty falling asleep and difficulty staying asleep in adults.

What made this approval distinctive was the absence of a hard duration-of-use cap. Earlier nonbenzodiazepine hypnotics such as zolpidem (Ambien, approved 1992) and zaleplon (Sonata, approved 1999) carried label language explicitly discouraging use beyond 7 to 10 days. The eszopiclone NDA included a 6-month randomized controlled trial, which gave the FDA sufficient evidence to approve long-term use without attaching that same restriction.

The NDA and Supporting Trial Data

The key trial underpinning the long-term indication was the six-month polysomnography study by Krystal et al., published in Sleep in 2003 [1]. That trial enrolled 788 adults with chronic primary insomnia and randomized them to eszopiclone 3 mg or placebo nightly for 6 months. Patients in the eszopiclone arm showed statistically significant improvement in sleep latency, total sleep time, and waking after sleep onset compared with placebo at all assessment timepoints through month 6 (P<0.001 for all primary endpoints). No tolerance or rebound insomnia was observed over the 6-month period on drug, which was a notable finding for a Schedule IV agent.

Short-term studies also supported the 1 mg and 2 mg doses, particularly for older adults and patients with comorbid insomnia, providing the dose-ranging data the FDA needed to approve all three strengths simultaneously [2].

DEA Scheduling at Approval

Because eszopiclone acts at the GABA-A receptor complex, the DEA classified it as a Schedule IV controlled substance at the time of FDA approval. This placed it in the same category as other "Z-drugs" including zolpidem, zaleplon, and triazolam. Schedule IV designation requires a triplicate or electronic prescription in states that mandate it, limits refills to five within six months, and signals recognized abuse potential, even if lower than Schedule II or III agents [3].

How Has the Lunesta Label Changed Over Time?

The Lunesta prescribing information has been revised at least six times since 2004. Each revision reflects either new safety data, FDA-initiated class-wide actions, or post-market pharmacokinetic findings.

2007: Complex Sleep Behavior Warning Added

In March 2007, the FDA issued a class-wide safety communication requiring all sedative-hypnotic products, including eszopiclone, to add stronger label warnings about complex sleep behaviors [4]. These behaviors include sleepwalking, sleep-driving, making phone calls, and preparing and eating food while not fully awake. The 2007 label update also required manufacturers to send a Dear Healthcare Provider letter and to develop a Medication Guide for patients.

The FDA's decision followed adverse event reports accumulated in the MedWatch spontaneous reporting system. While the exact number of eszopiclone-specific reports was not published in isolation, the agency's review covered all approved nonbenzodiazepine hypnotics and concluded the risk was a class effect rather than drug-specific.

2013 to 2014: Dose Reduction for Next-Morning Impairment

This was the most clinically impactful label revision. In May 2013, the FDA issued a safety communication specifically about zolpidem's effect on next-morning driving ability, citing data showing elevated blood levels eight hours after a bedtime dose [5]. The FDA then extended this review to all nonbenzodiazepine hypnotics, including eszopiclone.

By January 2014, the FDA required Sunovion to revise the recommended starting dose of Lunesta. The previous label had recommended 2 mg as the standard adult starting dose. The revised label lowered the starting dose to 1 mg for all adults, with an option to increase to 2 mg or 3 mg if clinically needed [6]. For women specifically, the FDA noted that eszopiclone blood levels are higher at equivalent doses compared with men, a pharmacokinetic difference attributed to lower clearance rates in females. This was the same rationale applied to the zolpidem dose reduction the year before.

The FDA cited pharmacokinetic modeling data and driving simulation studies showing that eszopiclone 3 mg could produce next-morning blood levels sufficient to impair driving performance. Residual sedation at 7.5 to 9 hours post-dose was the threshold of concern.

2019: Black Box Warning for Complex Sleep Behaviors

The 2007 warning language, while substantive, was placed in the Warnings and Precautions section of the label. In April 2019, the FDA escalated this to a Boxed Warning, the most prominent type of safety alert in FDA label architecture, for all Z-drugs including eszopiclone [7].

The Boxed Warning states that rare but serious injuries and deaths have occurred as a result of complex sleep behaviors. The FDA's decision was based on a review of 66 cases in the FDA Adverse Event Reporting System (FAERS) involving serious injuries or death, including drowning, falls, and motor vehicle accidents, associated with complex sleep behaviors while taking nonbenzodiazepine hypnotics. Of those 66 cases, 20 were fatal.

The 2019 update also added a contraindication: eszopiclone is now contraindicated in patients who have previously experienced a complex sleep behavior episode while taking any hypnotic. This represents a shift from the earlier approach, which treated the behavior as a warning rather than an absolute stop signal.

The HealthRX clinical team uses the following decision framework when evaluating eszopiclone candidacy: (1) screen for prior complex sleep behavior episodes before prescribing any hypnotic; (2) start at 1 mg regardless of patient age or sex; (3) reassess at 2 weeks and 4 weeks using a validated tool such as the Insomnia Severity Index (ISI); (4) for patients who report residual morning sedation at 1 mg, do not increase the dose before ruling out sleep apnea or drug interactions with CYP3A4 inhibitors; and (5) document the counseling discussion about complex sleep behaviors in the visit note.

What Does the Current Lunesta Label Say?

The current Lunesta prescribing information, available through FDA Drugs@FDA under NDA 021476, covers indications, dosing, contraindications, warnings, drug interactions, and pharmacology [6].

Approved Indications and Dosing

Lunesta is indicated for the treatment of insomnia in adults. The label does not restrict use to a specific number of nights, which remains unusual among approved hypnotics.

Dosing recommendations as of the 2014 revision:

• Adults: 1 mg immediately before bedtime. May increase to 2 mg or 3 mg if needed. Do not exceed 3 mg per night.
• Elderly or debilitated patients: 1 mg immediately before bedtime. Maximum dose is 2 mg.
• Severe hepatic impairment: Do not exceed 2 mg.
• Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Do not exceed 1 mg.

The label instructs patients to take eszopiclone only when they have at least 7 to 8 hours available before planned awakening, a directive added and reinforced through the 2014 revision [6].

Contraindications

The current label lists one absolute contraindication: a history of complex sleep behavior (sleepwalking, sleep-driving, or other complex behaviors) while taking eszopiclone or any other hypnotic. This contraindication was added in 2019 with the Boxed Warning upgrade [7].

There is no contraindication based solely on age or renal function, though dose adjustments are recommended for hepatic impairment and concurrent CYP3A4 inhibitor use.

Drug Interactions

Eszopiclone is metabolized primarily by CYP3A4 and CYP2E1. Co-administration with potent CYP3A4 inhibitors increases eszopiclone AUC significantly. A drug interaction study with ketoconazole 400 mg increased eszopiclone AUC by approximately 2.2-fold, which is the pharmacokinetic basis for the 1 mg dose cap in that setting [6].

Additive CNS depression occurs with other sedatives, opioids, alcohol, and antihistamines. The label advises against co-administration with any CNS depressant unless the benefit clearly outweighs the risk.

What Are the Key Safety Findings From Post-Market Surveillance?

Since 2004, real-world safety data have accumulated through FAERS, FDA Sentinel, and published post-market studies. The picture that emerges is broadly consistent with what the clinical trials showed, with a few notable findings that drove label changes.

Falls and Fractures in Older Adults

Older adults taking any sedative-hypnotic face a documented risk of falls and fall-related fractures. A 2012 cohort analysis using Medicare data found that nonbenzodiazepine hypnotic users aged 65 and older had a significantly elevated odds of hip fracture compared with non-users [8]. The analysis did not isolate eszopiclone from zolpidem or zaleplon, but the signal applied across the class. The current Lunesta label reflects this with dose caps in elderly patients and a specific Warnings and Precautions statement about impaired motor function.

Dependence and Withdrawal

Because eszopiclone is Schedule IV, prescribers must consider physical dependence with prolonged use. The label acknowledges that abrupt discontinuation after nightly use can produce withdrawal symptoms including rebound insomnia, anxiety, and in rare cases, seizures (the latter documented primarily with benzodiazepines but considered a class-level precaution) [6].

Clinical guidance from the American Academy of Sleep Medicine (AASM) recommends a gradual taper rather than abrupt cessation for patients who have used eszopiclone for more than 4 weeks [9]. The AASM 2017 guideline states: "We suggest that clinicians use a dose taper when discontinuing chronic hypnotic therapy to minimize withdrawal symptoms and rebound insomnia."

Abuse Potential: FDA Sentinel Data

The FDA Sentinel system, which draws on claims data from over 100 million insured patients, has monitored Z-drug misuse since 2012. A 2018 Sentinel analysis found that eszopiclone had lower rates of misuse-related claims compared with zolpidem, though both remained well above background rates for non-controlled medications [10]. The relative misuse rate for eszopiclone was approximately 2.4 per 1,000 patient-years in that dataset, compared with 6.7 per 1,000 patient-years for zolpidem extended-release.

This finding has not changed eszopiclone's Schedule IV classification, but it supports the clinical impression that eszopiclone carries somewhat lower misuse potential than zolpidem at equivalent prescribed doses.

When Did Lunesta Generics Become Available?

The FDA approved the first generic eszopiclone tablets in April 2014, following the expiration of Sepracor/Sunovion's method-of-use and compound patents. Multiple manufacturers received approval simultaneously, including Mylan, Teva, and Amneal, creating a competitive generic market that reduced the out-of-pocket cost substantially [11].

Generic eszopiclone is therapeutically equivalent to brand Lunesta and carries the same prescribing information requirements, including the Boxed Warning about complex sleep behaviors added in 2019.

How Does Eszopiclone's Regulatory History Compare With Other Z-Drugs?

Understanding where eszopiclone sits relative to zolpidem and zaleplon helps clinicians and patients interpret the regulatory record accurately.

Comparative Approval Timeline

• Zolpidem (Ambien): FDA approved December 16, 1992, under NDA 019908. Available in 5 mg and 10 mg tablets. Dose reduction required in 2013 for immediate-release and extended-release formulations due to next-morning impairment data, with women's starting dose reduced to 5 mg [5].
• Zaleplon (Sonata): FDA approved August 13, 1999, under NDA 020859. Approved at 5 mg and 10 mg. No major dose revision has been required, partly because its ultra-short half-life (approximately 1 hour) makes next-morning residual sedation less likely.
• Eszopiclone (Lunesta): FDA approved December 15, 2004, under NDA 021476. The longest approved clinical trial record among the three, supporting chronic use labeling from the start [2].

Unique Regulatory Features of Eszopiclone

Two features make eszopiclone's regulatory history distinct. First, no upper duration-of-use limit appears in the approved label, while zaleplon and original zolpidem labeling cautioned against use beyond 7 to 10 days. Second, eszopiclone underwent a class-driven dose reduction in 2014 that was slightly less dramatic than zolpidem's: the recommended starting dose went from 2 mg to 1 mg rather than being cut in half for all patients as zolpidem's was for women.

The 2019 Boxed Warning applies equally across all three drugs, standardizing the most critical safety communication at the class level.

What Does the FDA Currently Recommend for Clinicians Prescribing Lunesta?

The FDA's current guidance, reflected in the approved prescribing information and associated medication guides, can be summarized across four areas.

Patient Screening Before Prescribing

Prescribers should ask patients about any previous episode of sleepwalking, sleep-driving, or other complex behavior while taking a sleep aid. If the patient reports such a history, the current label contraindicates eszopiclone use entirely [7].

Starting Dose and Titration

Begin at 1 mg for all adults. Increase to 2 mg or 3 mg only if the 1 mg dose proves insufficient and the patient tolerates the lower dose without significant next-morning impairment. For patients who report grogginess, light-headedness, or driving difficulty the morning after a dose, do not increase; instead, investigate contributing factors such as co-administered CNS depressants or undiagnosed sleep apnea [6].

Duration of Use and Monitoring

The FDA does not restrict duration, but the AASM recommends re-evaluating patients on chronic hypnotic therapy at least every 3 months [9]. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per AASM guidelines, with pharmacotherapy positioned as an adjunct or short-term bridge.

Patient Counseling

The Medication Guide (required for each dispensed prescription) instructs patients not to take eszopiclone unless they have a full 7 to 8 hours to sleep, not to drive or operate heavy machinery until they know how the drug affects them in the morning, not to drink alcohol, and to call a clinician immediately if they experience any complex sleep behavior.